Strong Core, Lithium Capex Drag — the ₹7,000 Crore Question

Exide delivered a strong headline: ₹5,528 crore revenue (+17.7% YoY) and ₹351 crore PAT (+27.9% YoY), with EBITDA margin expanding 20 basis points to 12.4% despite raw material and currency headwinds. Broad-based growth across auto OEM (+25%), 2W/4W replacements, solar (record ₹400+ crore), and inverters drove the beat. But management declined to raise full-year guidance. The call reveals why: Q1 benefited from seasonal factors (summer inverter peak, monsoon timing), H2 comparables are punishing, and the real story is ₹4,902 crore already invested in lithium-ion, with another ₹1,400 crore approved for FY27 — all pre-revenue. This is a company running two engines at radically different stages of maturity.

The core lead-acid business — auto OEM, replacements, inverters, solar — is humming. Broad-based volume growth (auto OEM +21% volume, 2W OEM +20%, 4W replacement +10%, solar +12–14%) combined with calibrated pricing (4–6% YoY) to drive revenue. EBITDA margin expanded 20 basis points despite elevated lead costs and rupee weakness, signaling cost discipline. This is textbook execution in a mature, competitive space.

But three factors made Q1 look better than the underlying trend:

Management flagged all three on the call and explicitly warned that H2 FY26 saw the post-GST boom (Q3–Q4), creating high comparables for the second half of FY27. Do not expect +25% auto OEM growth to continue sequentially.

Exide has invested ₹4,902 crore across four production lines (NMC cylindrical, LFP prismatic for 2W/3W, and additional capacity for 4W and stationary). As of quarter-end, samples have commenced. Management targets 25–30% plant utilization in FY27 and full commercialization ramp in the second half.

This timeline is achievable but not yet proven. Yields are improving, but the MD acknowledged that real yield visibility comes only at full 3-shift operation, not sample scale. Customer homologation is ongoing; no serial production volume commitments yet. The 2W OEM engagement covers 3 major players representing ~80% of the EV market; the company expects to be 'another supplier,' not sole source. Raw material supply remains 100% import (Chinese); localization of BOM to 50–60% will take 2–3 years.

The market's reaction was muted: day 1 −0.64%, day 3 +1.25%. After an initial dip, a modest recovery — neither a strong conviction buy nor a confident sell. The stock is now at ₹467, which is −2.45% from its all-time high of ₹478.75 but +62.66% off its 52-week low of ₹287.1. RSI of 69.5 is neutral, suggesting room for upside if sentiment improves.

Ownership tells a quieter story. Foreign investors trimmed 62 basis points to 10.30% (from 10.92% in the prior quarter), a subtle signal of caution. Domestic institutional investors added 42 basis points to 19.13%, offsetting the FII reduction. Promoters remain steady at 45.99%. The FII trim — during a quarter of strong headline growth — suggests skepticism about the lithium capex ROI and/or valuation at peak enthusiasm for EV exposure.

Volume trend is increasing, indicating continued retail and tactical interest, but the mix of strong growth + muted price action + FII trimming suggests the street is pricing in the capex drag and waiting for concrete proof of lithium commercialization.

The honest read: Exide is executing well on the core and appears to be executing competently on lithium (4 lines operational, samples out, R&D backed, multiple partnerships). But this is a steady execution story, not a step-change quarter. The reported growth is real, but Q1 was seasonally favorable; H2 will be harder. Lithium is on the roadmap and de-risked technically, but commercialization is still 6–12 months away, and material earnings contribution is 3–5 years away. For investors at ₹467, you are pricing in lithium success and 70–80% utilization by FY28–29. The street's muted reaction (FII trim, day-1 dip) signals that bar is increasingly priced in, leaving room for disappointment. The debate is no longer "will lithium work," but "when, and at what margin."

Core PAT (ex-lithium losses/capex write-downs). Watch whether FY27 core PAT sustains at ₹350+ crore, adjusted for seasonal factors. If sequential growth decelerates below low-single-digit levels in H2, the core thesis weakens, and lithium becomes the only upside — a higher-risk situation. Lithium contribution will remain near-zero through FY27; the first meaningful lithium earnings impact (even if breakeven-level) will be a narrative inflection point.